Alaya.bio

Alaya.bio is a biotech developing a targeting polymeric nanoparticle platform for CAR‑T cell immunotherapies, with an emphasis on in situ (in vivo) approaches. The company’s platform is described as using targeting agents grafted onto a polymeric nanoparticle shell to direct nanoparticles to T cells, with the goal of efficient and safe delivery of therapeutic payloads. Alaya.bio states that its nanoparticle enhances transduction efficiency of quiescent cells such as T cells and NK cells while preserving naive and memory phenotypes, and that it can be used either ex vivo (as part of rapid manufacturing processes) or in vivo (in situ transduction after systemic administration). [1][4][6]

Alaya.bio positions its approach as a way to address hurdles of traditional ex vivo CAR‑T therapies, including complexity, long manufacturing cycles, and high cost. Its collaboration announcement describes advancing research into in situ CAR‑T cell therapies with a focus on evaluating faster, more effective, and cost‑efficient treatments; it also describes a plan to advance the polymeric delivery platform toward clinical translation in hematological malignancies. Separately, Alaya.bio’s acquisition of key assets from Ixaka France is described as providing preclinical proof-of-concept data for in vivo engineered CAR‑T cells and intellectual property supporting its in vivo gene delivery platform. [4][6]